|
Kalp Yetersizliği ÇG
Yönetim Kurulu
Başkan:
Dr. Özlem Yıldırımtürk
Y.K. adına Koordinatör:
Dr. Dursun Aras
Y.K. adına Koordinatör:
Dr. Bülent Mutlu
Üyeler
Dr. K. Emre Aslanger
Dr. Zübeyde Bayram
Dr. Ali Kemal Kalkan
Dr. Hakkı Kaya
Dr. Taner Şen
Sayı Sorumlusu:
Doç. Dr. Özlem Yıldırımtürk
Katkıda Bulunanlar:
Doç. Dr. Özlem Yıldırımtürk, Doç. Dr. Hakan Altay
|
|
Geçmiş anket sonuçları
Bülten İstek Formu
|
KY Bülteni - Kalp Yetersizliği Elektronik Haber Bülteni / "2018 ESC Münih Kongresinde Kalp Yetersizliği İle İlgili Dikkat Çeken Çalışmalar" Ekim 2018 (4)
| 2018 ESC Münih Kongresinde Kalp Yetersizliği İle İlgili Dikkat Çeken Çalışmalar |
| | PROMIS-HFpEF- Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction. | | | Dergi: ESC Congress, 2018 Munih, 25-29 August 2018 | | | ... | | | Dr. Özlem Yıldırımtürk | | |  | |
| | MITRA-FR study - A randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation and reduced left ventricular ejection fraction. | | | Dergi: ESC Congress, 2018 Munih, 25-29 August 2018 | | | ... | | | Dr. Özlem Yıldırımtürk | | | | |
| | TRANSITION study-Initiation of sacubitril/valsartan in hospitalized patients with heart failure with reduced ejection fraction after hemodynamic stabilization: Primary results of TRANSITION study. | | | Dergi: ESC Congress, 2018 Munih, 25-29 August 2018 | | | ... | | | Dr. Özlem Yıldırımtürk | | | | |
| | COMMANDER HF study - Multicenter, randomized, double-blind, placebo-controlled, event-driven trial assessing the effectiveness and safety of rivaroxaban in reducing the risk of death, myocardial infarction, or stroke in patients with heart failure and coronary artery disease following an episode of decompensated heart failure. | | | Dergi: ESC Congress, 2018 Munih, 25-29 August 2018 | | | ... | | | Dr. Hakan Altay | | | | |
| | ATTR-ACT - Muticentre randomized placebo-controlled trial evaluating the efficacy of tafamidis on mortality, cardiovascular hospitalization and quality of life in patients with hereditay and wild type transthyretin amyloid | | | Dergi: ESC Congress, 2018 Munih, 25-29 August 2018 | | | ... | | | Dr. Hakan Altay | | | | |
|
